Applied BioMath, a company that deals with implementing systems pharmacology and mechanistic modelling, simulation, and analysis to de-risk drug research and development, has collaborated with Verseau Therapeutics, a company creating a new range of therapeutics, macrophage checkpoint modulators, it was reported on Monday.

The collaboration is aimed at the development and delivery of a systems pharmacology model. The model is to be utilised for efficacious dose prediction for the treatment of cancer.

Dr Tatiana Novobrantseva, co-founder and chief scientific officer of Verseau Therapeutics, said, 'We previously collaborated with Applied BioMath to evaluate the therapeutic feasibility of a series of assets. We look forward to extending this collaboration to predict an efficacious dose for one of our lead macrophage checkpoint inhibitor programs. The intersections between mathematical models and experimental drug development will yield more translatable experiments and better-informed clinical trials.'